ABSTRACT
The SNO+ Collaboration reports the first evidence of reactor antineutrinos in a Cherenkov detector. The nearest nuclear reactors are located 240 km away in Ontario, Canada. This analysis uses events with energies lower than in any previous analysis with a large water Cherenkov detector. Two analytical methods are used to distinguish reactor antineutrinos from background events in 190 days of data and yield consistent evidence for antineutrinos with a combined significance of 3.5σ.
ABSTRACT
Endostatin is a cleavage product of collagen XVIII that inhibits tumor angiogenesis and growth. Interferon alpha2a blocks tumor angiogenesis and causes regression of hemangiomas, but has no effect on choroidal neovascularization (CNV). Therefore, inhibitors of tumor angiogenesis do not necessarily inhibit ocular neovascularization. In this study, we used an intravenous injection of adenoviral vectors containing a sig-mEndo transgene consisting of murine immunoglobulin kappa-chain leader sequence coupled to sequence coding for murine endostatin to investigate the effect of high serum levels of endostatin on CNV in mice. Mice injected with a construct in which sig-mEndo expression was driven by the Rous sarcoma virus promoter had moderately high serum levels of endostatin and significantly smaller CNV lesions at sites of laser-induced rupture of Bruch's membrane than mice injected with null vector. Mice injected with a construct in which sig-mEndo was driven by the simian cytomegalovirus promoter had approximately 10-fold higher endostatin serum levels and had nearly complete prevention of CNV. There was a strong inverse correlation between endostatin serum level and area of CNV. This study provides proof of principle that gene therapy to increase levels of endostatin can prevent the development of CNV and may provide a new treatment for the leading cause of severe loss of vision in patients with age-related macular degeneration.
Subject(s)
Angiogenesis Inhibitors/genetics , Choroid/blood supply , Collagen/genetics , Genetic Therapy/methods , Neovascularization, Pathologic/prevention & control , Peptide Fragments/genetics , Adenoviridae/genetics , Angiogenesis Inhibitors/blood , Animals , Collagen/blood , Collagen Type XVIII , Endostatins , Gene Expression , Genes, Reporter/genetics , Genetic Vectors , Injections, Intravenous , Liver/physiology , Mice , Mice, Inbred C57BL , Neovascularization, Pathologic/pathology , Ocular Physiological Phenomena , Peptide Fragments/blood , Recombination, GeneticABSTRACT
HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-oncogene, develop spontaneous focal mammary adenocarcinomas beginning at 5-6 months of age. The development and histology of these tumors bears a striking resemblance to what is seen in patients with breast cancer. We have characterized the immunological responses to HER-2/neu (neu) in this animal model. neu-positive tumor lines, which were derived from spontaneous tumors that formed in neu-N animals, are highly immunogenic in parental, FVB/N mice. In contrast, a 100-fold lower tumor challenge is sufficient for growth in 100% of transgenic animals. Despite significant tolerance to the transgene, neu-specific immune responses similar to those observed in breast cancer patients can be demonstrated in neu-N mice prior to vaccination. Both cellular and humoral neu-specific responses in transgenic mice can be boosted with neu-specific vaccination, although to a significantly lesser degree than what is observed in FVB/N mice, indicating that the T cells involved are less responsive than in the nontoleragenic parental strain. Using irradiated whole-cell and recombinant vaccinia virus vaccinations we are able to protect neu-N mice from a neu-expressing tumor challenge. T-cell depletion experiments demonstrated that the observed protection is T cell dependent. The vaccine-dependent neu-specific immune response is also sufficient to delay the onset of spontaneous tumor formation in these mice. These data suggest that, despite tolerance to neu in this transgenic model, it is possible to immunize neu-specific T cells to achieve neu-specific tumor rejection in vivo. These transgenic mice provide a spontaneous tumor model for identifying vaccine approaches potent enough to overcome mechanisms of immune tolerance that are likely to exist in patients with cancer.
Subject(s)
Adenocarcinoma/genetics , Adenocarcinoma/immunology , Cancer Vaccines , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/immunology , Receptor, ErbB-2/immunology , T-Lymphocytes/immunology , 3T3 Cells , Adenocarcinoma/therapy , Animals , Female , Genes, erbB-2 , Immune Tolerance , Mammary Neoplasms, Experimental/therapy , Mice , Mice, Inbred Strains , Mice, Transgenic , Rats , Receptor, ErbB-2/genetics , Reverse Transcriptase Polymerase Chain Reaction , Thymus Gland/immunologyABSTRACT
Our laboratory has previously reported the isolation of a murine cDNA which restores reduced folate carrier (RFC) activity and methotrexate (MTX) sensitivity to a MTX-resistant, transport-deficient human breast cancer cell line (MTXR ZR-75-1) (K. H. Dixon et al., J. Biol. Chem., 269: 17-20, 1994). Using this murine cDNA as a probe, we have isolated two homologous overlapping partial cDNAs from a human testis cDNA library. In addition, using human cDNA as a probe, we have isolated a 20-kb human genomic fragment which contains RFC coding regions. Analysis of the nucleotide sequence of these clones revealed that the human RFC gene, RFC1, is approximately 65% homologous to the murine and hamster genes. Using a human genomic P1 plasmid clone containing RFC1, we mapped the location of RFC1 by fluorescence in situ hybridization to the end of the long arm of chromosome 21 (21q22.2-q22.3). Fluorescence in situ hybridization analysis also showed that two copies of RFC1 were present in MTXR ZR-75-1 cells, and showed no evidence of rearrangement of this gene. Northern blot analysis of MTXR ZR-75-1 cells demonstrated a marked decrease in the level of the 3-kb RFC1 transcript relative to the parental cell line, and Western blot analysis using a polyclonal antibody raised against a peptide generated from the RFC1 sequence showed decreased expression of an approximately M(r) 56,000 protein in MTXR ZR-75-1 cells. Finally, MTXR ZR-75-1 cells transfected with an RFC1 gene showed increased MTX uptake, which was more sensitive to competition by folinic acid than by folic acid. Therefore, decreased RFC1 expression appears to be the molecular mechanism of decreased MTX uptake in this MTX-resistant cell line.
Subject(s)
Breast Neoplasms/genetics , Carrier Proteins/genetics , Folic Acid/metabolism , Membrane Proteins/genetics , Membrane Transport Proteins , Amino Acid Sequence , Base Sequence , Breast Neoplasms/metabolism , Carrier Proteins/chemistry , Drug Resistance , Gene Expression Regulation, Neoplastic , Humans , In Situ Hybridization, Fluorescence , Membrane Proteins/chemistry , Methotrexate , Molecular Sequence Data , Molecular Weight , Tumor Cells, CulturedABSTRACT
Mammalian cells accumulate reduced folates and methotrexate, a folate antagonist, through the reduced-folate carrier (RFC) (Goldman, I.D., Lichtenstein, N.S., and Oliverio, V.T. (1968) J. Biol. Chem. 243, 5007-5017). This study describes the isolation and expression of a cDNA clone that restores RFC activity to human breast cancer cells defective in this transporter. The cDNA cancer cells defective in this transporter. The cDNA codes for a peptide (mRFC1) of 58 kDa, whose hydropathy plot, resembling those of mammalian sugar transporters, predicts that it may be a member of a superfamily of transporter genes. Transfection of methotrexate-resistant (MTXR) ZR-75-1 cells with an expression vector, pRFC1, that codes for this peptide restores their ability to accumulate methotrexate. Furthermore, transport of methotrexate into pRFC1-transfected cells is blocked by a 10-fold molar excess of the reduced folate, 5-formyltetrahydrofolic acid, but is unaffected by folic acid. The increase in methotrexate uptake that is observed in pRFC1-transfected MTXR ZR-75-1 cells reverses their resistance to this antitumor agent.
Subject(s)
Carrier Proteins/genetics , Folic Acid/metabolism , Membrane Proteins , Membrane Transport Proteins , Methotrexate/pharmacology , Amino Acid Sequence , Animals , Base Sequence , Biological Transport , Carrier Proteins/metabolism , DNA, Complementary , Humans , Mice , Molecular Sequence Data , Reduced Folate Carrier Protein , Transfection , Tumor Cells, CulturedABSTRACT
A major problem in cancer therapy is tumor drug resistance such as is found with antifolates (e.g., methotrexate [MTX]). We are specifically interested in the role of the human folate receptor (hFR) in MTX resistance. To investigate whether transfection of hFR results in increased MTX uptake and increased drug sensitivity, human mammary carcinoma (MCF-7) cells and Chinese hamster ovary cells (CHO) (cells which do not express detectable levels of hFR) were transfected with hFR cDNA. Stable human mammary carcinoma and Chinese hamster ovary transfectants expressing high levels of hFR were selected for further analysis. Transfected cells which express increased levels of hFR grow more rapidly than mock transfected or wild type cells in media containing physiologic concentrations of folates. The hFR expressed by these cells is sorted to the plasma membrane and is functional as determined by cell surface binding of a radiolabeled folic acid derivative and by internalization of [3H]methotrexate. The stable transfectants that express increased levels of hFR are also more sensitive to MTX in physiologic concentrations of folates. We conclude that increased expression of hFR by human mammary carcinoma and Chinese hamster ovary cells cultured under these conditions results in an enhanced growth rate, increased folic acid binding, and increased MTX uptake and cytotoxicity.
Subject(s)
Carrier Proteins/genetics , Drug Resistance/physiology , Folic Acid Antagonists/pharmacology , Methotrexate/pharmacology , Animals , CHO Cells/physiology , Cricetinae , DNA, Recombinant/genetics , Folate Receptors, GPI-Anchored , Folic Acid/metabolism , Humans , Immunoblotting , KB Cells/ultrastructure , RNA/analysis , Receptors, Cell Surface/genetics , Transfection , Tumor Cells, Cultured/physiologyABSTRACT
This review examines the hypothesis that glutathione and its associated enzymes contribute to the overall drug-resistance seen in multidrug resistant cell lines. Reports of 34 cell lines independently selected for resistance to MDR drugs are compared for evidence of consistent changes in activity of glutathione-related enzymes as well as for changes in glutathione content. The role of glutathione S-transferases in MDR is further analyzed by comparing changes in sensitivity to MDR drugs in cell lines selected for resistance to non-MDR drugs that have resulting increases in glutathione S-transferase activity. In addition, results of studies in which genes for glutathione S-transferase isozymes were transfected into drug-sensitive cells are reviewed. The role of the glutathione redox cycle is examined by comparing changes in elements of this cycle in MDR cell lines as well as by analyzing reports of the effects of glutathione depletion on MDR drug sensitivity. Overall, there is no consistent or compelling evidence that glutathione and its associated enzymes augment resistance in multidrug resistant cell lines.
Subject(s)
Antineoplastic Agents/toxicity , Carrier Proteins/metabolism , Drug Resistance/physiology , Glutathione Transferase/metabolism , Glutathione/metabolism , Membrane Glycoproteins/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Animals , Carrier Proteins/biosynthesis , Carrier Proteins/genetics , Cell Line , Drug Resistance/genetics , Female , Glutathione Transferase/biosynthesis , Humans , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Oxidation-Reduction , Tumor Cells, CulturedABSTRACT
Two biochemically distinct systems, the high affinity folate receptor and the lower affinity reduced-folate carrier, have each been implicated in mediating the transport of folates and antifolates into cells. Previous studies from our laboratory have shown that methotrexate accumulation into wild type (WT) ZR-75-1 human breast cancer cells involves a system with characteristics of the reduced-folate carrier, that this system is deficient in methotrexate resistant (MTXR) ZR-75-1 cells in which methotrexate transport is undetectable and that neither breast cancer cell line expresses folate receptors. In this report we examined the possible interaction of the reduced-folate carrier with folate receptors by stably transfecting both WT ZR-75-1 and MTXR ZR-75-1 cells with an expression vector containing a folate receptor cDNA. Clones of stably transfected MTXR ZR-75-1 and WT ZR-75-1 cells expressing comparable levels of folate receptors were studied and compared to the nontransfected cell lines. Although nontransfected WT and MTXR ZR-75-1 cell lines require concentrations > or = 100 nM folic acid for growth, the expression of folate receptors in transfected WT and MTXR ZR-75-1 cells permitted the growth of both cell lines in low concentrations (1 nM) of folic acid. While the defect in the reduced-folate carrier system in MTXR ZR-75-1 cells inhibits their growth in medium containing low concentrations of folinic acid (< or = 1 microM), MTXR ZR-75-1 cells expressing folate receptors display uninhibited growth in 1 nM folinic acid. The accumulation of folic acid, folinic acid, and methotrexate is enhanced in folate receptor-transfected WT ZR-75-1 cells and MTXR ZR-75-1 cells. Furthermore, the accumulation of folates and antifolate was similar in both transfected WT and MTXR ZR-75-1 cell lines that expressed folate receptors. This suggests that alterations in the reduced-folate carrier do not affect folate receptor function. We also examined the effect of folate receptor expression on the sensitivity of WT and MTXR ZR-75-1 cells to methotrexate and to the lipophillic antifolate trimetrexate. Increased folate receptor expression decreased the sensitivity of WT ZR-75-1 cells toward the antifolate trimetrexate, presumably through increased uptake of reduced folates. Although the expression of the folate receptor enhanced the growth of both cell lines in low folate concentrations, it did not affect the sensitivity of either WT or MTXR ZR-75-1 cells to methotrexate.
Subject(s)
Carrier Proteins/genetics , Carrier Proteins/metabolism , Folic Acid/metabolism , Methotrexate/metabolism , Receptors, Cell Surface , Biological Transport , Blotting, Northern , Breast Neoplasms , Cell Division/drug effects , Cell Membrane/metabolism , Clone Cells , Female , Folate Receptors, GPI-Anchored , Genetic Vectors , Humans , Kinetics , Leucovorin/metabolism , Methotrexate/pharmacology , Transfection , Trimetrexate/pharmacology , Tumor Cells, CulturedABSTRACT
A mitoxantrone-resistant human MCF-7 breast cancer subline (MCF/MX) which is approximately 4000-fold resistant to mitoxantrone was isolated by serial passage of the parental wild-type MCF-7 cells (MCF/WT) in stepwise increasing concentrations of drug. MCF/MX cells were also approximately 10-fold cross-resistant to doxorubicin and etoposide but were not cross-resistant to vinblastine. Intracellular accumulation of radiolabeled mitoxantrone was markedly reduced in MCF/MX cells relative to that in the drug-sensitive MCF/WT cells. This decrease in intracellular drug accumulation into MCF/MX cells was associated with enhanced drug efflux, which was reversed when cells were incubated in the presence of sodium azide and 2, 4-dinitrophenol, suggesting an energy-dependent process. Incubation of MCF/MX cells with verapamil did not affect either the accumulation of mitoxantrone or the level of resistance in these cells. Furthermore, RNase protection and Western blot analyses failed to detect the expression of the mdr1 RNA or P-glycoprotein, a drug efflux pump known to be associated with the development of multidrug resistance in vitro. However, a polyclonal antibody directed against a synthetic peptide corresponding to the putative ATP binding domain of P-glycoprotein reacted with two (M(r) 42,000 and 85,000) membrane proteins from MCF/MX cells which were not found in MCF/WT. Functional assays and Western blot analysis for topoisomerase II revealed no differences in topoisomerase II activity or protein levels in MCF/MX cells. Thus, resistance in this cell line is apparently associated with enhanced drug efflux involving a pathway distinct from the mdr1-encoded multidrug transporter P-glycoprotein.
Subject(s)
Breast Neoplasms/metabolism , Membrane Glycoproteins/physiology , Mitoxantrone/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Adenosine Triphosphate/biosynthesis , Adenosine Triphosphate/metabolism , Antibodies , Blotting, Western , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Cell Membrane Permeability/drug effects , Cell Membrane Permeability/physiology , Cross Reactions , DNA Topoisomerases, Type II/metabolism , Doxorubicin/pharmacology , Drug Resistance , Etoposide/pharmacology , Gene Expression/genetics , Humans , Intracellular Fluid/metabolism , Membrane Glycoproteins/genetics , Membrane Proteins/metabolism , Mitoxantrone/pharmacology , Tumor Cells, Cultured , Verapamil/pharmacologyABSTRACT
Fragments of the human glutathione S-transferase pi gene and 15 kb of its 5' flanking region have been fused to the chloramphenicol acetyl transferase (CAT) reporter gene. Transfection into a number of human cell lines (Hela, HepG2, MCF7 and EJ) has demonstrated that the AP1 binding site, located between nucleotides -58 and -65 (Cowell et al. 1988. Biochem. J. 255, 79-83), is essential for basal level promoter activity. We have also identified a positive cis-acting DNA element between nucleotides +8 and +72 which seems to be part of the promoter. No other regulatory activity was identified within the 17 kb analyzed.
Subject(s)
Glutathione Transferase/genetics , Isoenzymes/genetics , Promoter Regions, Genetic , Animals , Base Sequence , Binding Sites , Breast Neoplasms , Carcinoma, Hepatocellular , Cell Line , Chloramphenicol O-Acetyltransferase/genetics , Chloramphenicol O-Acetyltransferase/metabolism , DNA-Binding Proteins/metabolism , Exons , Female , Glutathione Transferase/metabolism , HeLa Cells/enzymology , Humans , Introns , Isoenzymes/metabolism , Liver Neoplasms , Molecular Sequence Data , Oligonucleotide Probes , Plasmids , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-jun , Rats , Recombinant Fusion Proteins/metabolism , Sequence Homology, Nucleic Acid , Transcription Factors/metabolism , Transfection , Urinary Bladder NeoplasmsABSTRACT
The mechanism of acquired methotrexate-resistance in an estrogen-receptor positive human breast cancer cell line (MTX(R)ZR-75-1) was studied. MTX(R) ZR-75-1 cells are 250-fold resistant to methotrexate when grown in the presence of 1 microM folinic acid and 2,400-fold resistant in the presence of 1 microM folic acid. This drug resistant cell line also showed collateral sensitivity (10-fold) to trimetrexate (TMQ), when grown in the presence of folinic acid. Using fluoresceinated methotrexate (F-MTX), FACS analysis indicated that there is no intracellular accumulation of methotrexate into MTX(R) ZR-75-1 cells, as determined by competition of F-MTX and methotrexate binding to dihydrofolate reductase. These characteristics strongly indicate that the mechanism of resistance involved down regulation of the reduced-folate transporter. To investigate this further, the transport kinetics of parental and MTX(R) ZR-75-1 cells were examined. Although the V(max) for methotrexate transport in wild-type (WT) ZR-75-1 breast cancer cells was 1-2 orders of magnitude lower than that in the well characterized leukemia cell lines, such as L1210 and CCRF-CEM cells, kinetic analysis indicated that transport of methotrexate into WT ZR-75-1 cells involved a mechanism that was similar if not identical to the reduced folate transporter. In contrast, no specific uptake of methotrexate was detected in MTX(R) ZR-75-1cells. Furthermore, neither cell line expressed detectable levels of folate binding protein, a binding protein with high affinity for folic acid as well as for reduced folates and antifolates. These results indicate that the level of expression of the reduced-folate carrier may be an important factor in determining the sensitivity of breast cancer cells as well as leukemia cells to antifolate compounds.
Subject(s)
Breast Neoplasms/drug therapy , Carrier Proteins/metabolism , Drug Resistance, Neoplasm , Folic Acid Antagonists/toxicity , Folic Acid/metabolism , Methotrexate/pharmacology , Receptors, Cell Surface/metabolism , Animals , Antimetabolites, Antineoplastic/pharmacology , Biological Transport , Breast Neoplasms/metabolism , Flow Cytometry , Folate Receptors, GPI-Anchored , Humans , Leucovorin/pharmacology , Leukemia/drug therapy , Leukemia/metabolism , Methotrexate/analogs & derivatives , Mice , Receptors, Estrogen/metabolism , Tetrahydrofolate Dehydrogenase/metabolism , Trimetrexate/pharmacology , Tumor Cells, Cultured , Vitamin B Complex/pharmacologyABSTRACT
We have examined regulation of the glutathione S-transferase pi gene by transient expression assay, and find that a fragment from 8 to 99 bp upstream of the cap site promotes transcription, but there is no evidence for any enhancer activity in a further 6 kb of flanking sequence. Analysis of this sequence by reference to a primate sequence database and Southern blotting revealed that as much as 5 kb of this flanking DNA were composed of repetitive insertion elements including an Alu and a LINE 1 repeat. The promoter fragment has been sequenced (Cowell et al (1988) Biochem. J. 255, 79-83) and contains a consensus AP1 binding site; in some cases, these have been associated with transcriptional induction by phorbol esters and ras oncogenes. We measured the steady state levels of glutathione S-transferase pi mRNA in human cell lines which were known to express ras oncogenes and compared them to human cell lines which have not been identified with ras activation. There was no correlation between expression of activated ras and expression of glutathione S-transferase pi mRNA. Treatment of HeLa cells, HepG2 cells and a small cell lung carcinoma line, GLC 8, with the phorbol ester 12-O-tetradecanoylphorbol 13-acetate failed to alter the steady state levels of endogenous glutathione S-transferase pi mRNA. The differences between these results and those of similar studies on rat glutathione S-transferase subunit 7, a structural orthologue of glutathione S-transferase pi, are discussed.
Subject(s)
Gene Expression Regulation , Glutathione Transferase/genetics , Animals , Blotting, Northern , Humans , Promoter Regions, Genetic , RNA, Messenger/analysis , Rats , Restriction Mapping , Tetradecanoylphorbol Acetate/toxicity , Transcription, GeneticABSTRACT
The human glutathione S-transferase pi gene has been isolated from a cosmid library. The gene spans approximately 3 kb, is interrupted by six introns and the region around its 5' end has the high G + C and CpG content typical of an HTF (HpaII tiny fragment) island. In addition to a TATA box at position -28 relative to the transcription initiation site and two G + C boxes (GGGCGG), the promoter contains a sequence motif matching the phorbol ester- and ras-responsive element from the polyoma virus enhancer.